Recent 8-K filings for VYNE
Highest-materiality recent filing
VYNE Therapeutics to merge with Yarrow Bioscience; Yarrow stockholders to own ~97% of combined company
- Pro forma ownership: pre-Merger Yarrow stockholders ~97%, VYNE stockholders ~3%.
- Pre-Closing Dividend of ~$14.5M to $16.5M to VYNE stockholders prior to close.
-
VYNE and Yarrow publish investor presentation for proposed merger
Yarrow Bioscience published an investor presentation on May 21, 2026, now available on VYNE's website.
-
VYNE receives Nasdaq extension to Sept 7, 2026 to regain $1 bid price compliance
Company failed to regain minimum $1.00 bid price by original March 10, 2026 deadline.
-
VYNE amends merger with Yarrow to allow pre-funded warrants and beneficial ownership cap
Amendment allows pre-funded warrants for Yarrow stockholders exceeding 9.99% beneficial ownership limit.
-
Pro forma ownership: pre-Merger Yarrow stockholders ~97%, VYNE stockholders ~3%.
-
VYNE Therapeutics annual meeting elects directors, ratifies auditor, approves say-on-pay
Class I directors Elisabeth Sandoval Little and Steven Basta elected with ~3.9M votes each.
-
VYNE reports Q3 net loss $7.3M; cash $32.7M; strategic review ongoing
Net loss $7.3M ($0.17 per share) vs $12.2M ($0.29) in Q3 2024; revenue $0.2M from Finacea royalty.
-
VYNE receives Nasdaq bid price deficiency notice; 180-day cure period to March 2026
Closing bid price of VYNE common stock below $1.00 for 30 consecutive business days.
-
VYNE Q2 net loss $5.8M; cash runway extended to H1 2027; two directors resign
Cash, equivalents and marketable securities $39.6M as of Jun 30, expected to fund ops into first half of 2027.
-
VYNE Phase 2b Repibresib vitiligo trial misses F-VASI50, terminates extension, seeks partner
Primary endpoint F-VASI50 at Week 24 not met: 19.5% for 3% vs 23.4% vehicle (p=0.1245).
-
Cash $50.3M; net loss $8.6M ($0.20/sh) vs $6.2M in Q1 2024.
-
VYNE reports FY2024 net loss $39.8M; cash $61.5M; repibresib Phase 2b data due mid-2025
Cash & equivalents total $61.5M as of Dec 31, 2024; expected runway into 2H 2026.
-
VYNE updates corporate presentation with previously announced Phase 1a data for VYN202
Phase 1a data for VYN202 and pipeline program updates included in presentation; data was previously announced.
-
VYNE reports positive Phase 1a MAD data for VYN202; no AE, robust biomarker activity
VYN202 showed favorable safety with no drug-related AEs, including no thrombocytopenia or neutropenia.
-
Stockholders approve 1.52M share increase in 2023 Equity Incentive Plan at annual meeting
Increase of 1,520,000 shares to 2023 Plan; total reserve now 1,651,907 shares.
-
VYNE reports Q3 net loss $12.2M; VYN201 Phase 2b enrollment exceeds target, top-line mid-2025
Net loss of $12.2M ($0.29/sh) in Q3 2024 vs $6.6M ($2.01/sh) in Q3 2023, driven by higher R&D spend.
-
VYNE Therapeutics reports positive Phase 1a SAD data for VYN202; no drug-related adverse events
VYN202 well tolerated across all dose groups; no serious or drug-related AEs, no clinically significant lab/ECG abnormalities.
-
VYNE Therapeutics Q2 2024 net loss $9.4M; cash $78.1M funds milestones into 2025
Net loss of $9.4M ($0.22 EPS) vs $10.1M ($3.09 EPS) in Q2 2023.
-
VYNE reports Q1 2024 net loss of $6.2M, cash $86M; vitiligo Phase 2b trial on track
Cash, equivalents, restricted cash and marketable securities of $86.0M as of March 31; runway through end of 2025.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.95 · Median 0.65 · Most common event earnings